Abivax SA (ABVX) - Total Liabilities

Latest as of December 2025: €129.14 Million EUR ≈ $150.97 Million USD

Based on the latest financial reports, Abivax SA (ABVX) has total liabilities worth €129.14 Million EUR (≈ $150.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ABVX shareholders equity momentum to track the company's year-over-year net asset growth rate.

Abivax SA - Total Liabilities Trend (2013–2025)

This chart illustrates how Abivax SA's total liabilities have evolved over time, based on quarterly financial data.

Abivax SA Competitors by Total Liabilities

The table below lists competitors of Abivax SA ranked by their total liabilities.

Company	Country	Total Liabilities
Nippon Life India Asset Management Limited NSE:NAM-INDIA	India	Rs5.33 Billion
GETLINK ADR EO-40 F:TNU	Germany	€6.35 Billion
Vibra Energia S.A. SA:VBBR3	Brazil	R$39.65 Billion
Quinenco SN:QUINENCO	Chile	CL$51.51 Trillion
Valmont Industries Inc NYSE:VMI	USA	$1.73 Billion
Canadian Utilities Limited TO:CU	Canada	CA$17.77 Billion
Redeia Corporacion S.A. MC:RED	Spain	€10.49 Billion
NTPC Green Energy Limited NSE:NTPCGREEN	India	Rs295.73 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Abivax SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abivax SA market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	8.75	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.28	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.22	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abivax SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abivax SA (2013–2025)

The table below shows the annual total liabilities of Abivax SA from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€129.14 Million ≈ $150.97 Million	-21.57%
2024-12-31	€164.64 Million ≈ $192.49 Million	+25.63%
2023-12-31	€131.05 Million ≈ $153.21 Million	+83.37%
2022-12-31	€71.47 Million ≈ $83.56 Million	-12.40%
2021-12-31	€81.59 Million ≈ $95.39 Million	+22.46%
2020-12-31	€66.62 Million ≈ $77.89 Million	+66.78%
2019-12-31	€39.95 Million ≈ $46.70 Million	+105.98%
2018-12-31	€19.39 Million ≈ $22.67 Million	+244.17%
2017-12-31	€5.63 Million ≈ $6.59 Million	+45.23%
2016-12-31	€3.88 Million ≈ $4.54 Million	-14.35%
2015-12-31	€4.53 Million ≈ $5.30 Million	+12.38%
2014-12-31	€4.03 Million ≈ $4.71 Million	-9.29%
2013-12-31	€4.44 Million ≈ $5.20 Million	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$10.08 Billion

€8.62 Billion EUR

Market Cap Rank

#2552 Global

#53 in France

Share Price

€108.70

Change (1 day)

+1.30%

52-Week Range

€58.80 - €135.00

All Time High

€135.00